Krystal Biotech, Inc. (KRYS)

Krystal Biotech's stock (KRYS) has experienced significant positive momentum in the past six months. The share price increased by 57.53% between January 2, 2025, and December 31, 2025, and saw an 83.75% increase over the past six months. Key events impacting the stock price include the FDA granting platform technology designation to the company's HSV-1 viral vector, strong financial performance in Q3 and Q4 2025, positive interim clinical updates from the Phase 1 CORAL-1 study evaluating KB407, the first patient dosed in the Phase 3 IOLITE clinical trial of KB803, analyst upgrades and price target increases, and the global expansion of VYJUVEK.

While detailed data on demand seasonality is limited, there may be minor fluctuations related to administrative processes or holiday periods. The core demand for Krystal Biotech's specialized genetic medicines for rare diseases is likely to be relatively stable, driven by ongoing medical need.

Krystal Biotech, Inc. is a global biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for diseases with high unmet medical needs. Their flagship product is VYJUVEK®, a redosable gene therapy approved in the United States, Europe, and Japan for dystrophic epidermolysis bullosa (DEB). The company is advancing a pipeline of genetic medicines across dermatology, respiratory, ophthalmology, and oncology.

Krystal Biotech is headquartered in Pittsburgh, Pennsylvania, and has a growing global presence. VYJUVEK has received regulatory approval in Europe and Japan in early and mid-2025, respectively, leading to commercial launches in markets such as Germany and France in late 2025.

Krystal Biotech has maintained a strong and positive brand reputation over the past year, driven by its innovative approach to genetic medicine and the successful commercialization of VYJUVEK. Key events contributing to its positive reputation include the FDA approval and global expansion of VYJUVEK, positive clinical trial results, analyst confidence, and financial strength. No significant negative events impacting Krystal Biotech's reputation have been identified in the past year.

Krystal Biotech has a diverse ownership structure, with a significant portion held by institutional investors and notable insider ownership. Major institutional owners include Fmr Llc, BlackRock, Inc., and Vanguard Group Inc. Key individual owners and insiders include Suma Krishnan, the largest individual shareholder, and Krish S. Krishnan.